Leukemia: all 5,475 studies
Page 39 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.
- Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of PlerixaforCompletedNCT01362985
- Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T CellsCompletedNCT01362452Phase 1
- Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is PossibleCompletedNCT01361334Phase 2
- S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based ChemotherapyCompletedNCT01360125
- Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic LeukemiaCompletedNCT01358253Phase 4
- Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+Status unknownNCT01354457Phase 1/2
- Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)CompletedNCT01352650Phase 1
- Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and LymphomaTerminatedNCT01352312Phase 1
- Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaCompletedNCT01351935Phase 1
- Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid LeukemiaCompletedNCT01347996Phase 4
- Genomic Analysis of Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT01346020
- Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping ImatinibCompletedNCT01343173Not applicable
- A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With DasatinibCompletedNCT01342679Phase 2
- Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)Status unknownNCT01339988Phase 4
- S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid LeukemiaCompletedNCT01338974
- WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular ElectroporationCompletedNCT01334060Phase 2
- Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid LeukemiaCompletedNCT01332786Phase 1
- Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic LeukemiaCompletedNCT01331590Early Phase 1
- Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML)Status unknownNCT01329471
- A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin LymphomaCompletedNCT01328626Phase 1
- Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell LeukemiaStatus unknownNCT01328236Phase 2
- Use of Lipid Emulsion or Nanoemulsion of Propofol on Children Undergoing Ambulatory Invasive Procedures.WithdrawnNCT01326078Phase 2/3
- Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)CompletedNCT01324180Phase 1
- A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)CompletedNCT01324063Phase 3
- Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid LeukemiaCompletedNCT01321385
- A Study Of Panobinostat In Children With Refractory Hematologic MalignanciesCompletedNCT01321346Phase 1
- POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric PatientsCompletedNCT01319864Phase 1
- Pre-hospital Risk Factors for Invasive Fungal InfectionStatus unknownNCT01315925
- Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic SyndromeCompletedNCT01314599Phase 1
- Establishment of Acute Lymphocytic Leukemia Data Base in the Department of OncologyStatus unknownNCT01310946
- Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01310101Phase 2
- Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT01310010Phase 2
- RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AMLStatus unknownNCT01307241
- A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)Active, not recruitingNCT01305499Phase 2
- Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)CompletedNCT01301820Phase 2
- TXA127 in Enhancement of Engraftment in Adult Double Cord Blood TransplantationTerminatedNCT01300611Phase 1
- AMG 319 Lymphoid Malignancy FIHCompletedNCT01300026Phase 1
- Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid LeukemiaCompletedNCT01298414
- Study of Long-Term Outcomes of Patients With Acute Lymphoblastic Leukemia Who Were Enrolled as Children on Clinical Trials EORTC-58741, EORTC-58831, EORTC-58832, or EORTC-58881 Between 1971 and 1998Status unknownNCT01298388
- Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for LeukemiaCompletedNCT01297543Phase 1/2
- PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 YearsStatus unknownNCT01296178Not applicable
- Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)Status unknownNCT01295593Phase 1/2
- Biomarker Study in Bone Marrow Samples From Patients With T-Cell Acute Lymphoblastic LeukemiaCompletedNCT01295476
- Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT01295307Phase 2
- Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT01294618Phase 2
- A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins LymphomaCompletedNCT01290549Phase 1
- Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid LeukemiaCompletedNCT01290107
- Empirical Versus Preemptive Antifungal TherapyCompletedNCT01288378Phase 3
- Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic LeukemiaCompletedNCT01284010
- Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid LeukemiaStatus unknownNCT01280786Phase 1
- Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)Status unknownNCT01279707Phase 1/2
- Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)CompletedNCT01279473Phase 1/2
- CLL Empirical Antibiotic RegimenCompletedNCT01279252Phase 2
- PET-CT in AML for Detection of Extramedullary AML ManifestationsCompletedNCT01278069
- Nonmyeloablative Allogeneic TransplantCompletedNCT01272817Not applicable
- A Drug Monitoring Study on PEG-asparaginase Treatment in Children Diagnosed Acute Lymphoblastic LeukaemiaStatus unknownNCT01272440
- Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic LeukemiaWithdrawnNCT01271283Phase 2
- Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)TerminatedNCT01265199Phase 1
- Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid LeukemiaTerminatedNCT01260714Phase 1
- A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid LeukaemiaCompletedNCT01256073Phase 1
- Antiviral Treatment of Chronic Lymphocytic LeukemiaCompletedNCT01255644Phase 4
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- PACE CALL: Weight Loss Study for Childhood Leukemia SurvivorsCompletedNCT01253720Not applicable
- Patient Reported Outcomes in Chronic Myeloid LeukemiaCompletedNCT01252589
- Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic LeukaemiaTerminatedNCT01251809Phase 1/2
- Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic LeukemiaCompletedNCT01251627Phase 2
- Azadirachta Indica in Treating Patients With Chronic Lymphocytic LeukemiaWithdrawnNCT01251250Phase 1
- Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid LeukemiaCompletedNCT01251159
- Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal DiseaseCompletedNCT01249820Phase 2
- Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01249430Phase 1
- Biomarkers in Samples From Young Patients With Acute Myeloid LeukemiaCompletedNCT01247584
- Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)CompletedNCT01247493Phase 2
- Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CRTerminatedNCT01246752Phase 3
- Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01246622Phase 1
- Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to TreatmentCompletedNCT01246557Phase 1/2
- Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid LeukemiaCompletedNCT01245231
- Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world SettingCompletedNCT01244750
- Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND OptimisationCompletedNCT01243489Phase 4
- Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)CompletedNCT01242774Phase 1
- Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological CancersStatus unknownNCT01240525Phase 2
- Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and AdolescentsStatus unknownNCT01239485Phase 1
- Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory LeukemiasWithdrawnNCT01239108Phase 1
- Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 MutationCompletedNCT01237808Phase 3
- A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.CompletedNCT01236144Phase 1/2
- Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive ChemotherapyCompletedNCT01235572Phase 2
- Azacitidine in Treating Patients With Chronic Myelomonocytic LeukemiaCompletedNCT01235117Phase 2
- Biomarkers in Tissue Samples From Patients With Acute Promyelocytic LeukemiaCompletedNCT01232855
- Biomarker Study in Tissue Samples From Patients With Acute Myeloid LeukemiaCompletedNCT01232842
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's LymphomaCompletedNCT01230983Phase 3
- Biomarkers in Tissue Samples From Young Patients With Acute Myeloid LeukemiaCompletedNCT01229956
- RNA Biomarkers in Tissue Samples From Infants With Acute Myeloid LeukemiaCompletedNCT01229124
- Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALLCompletedNCT01228331Phase 2/3
- A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid LeukemiaCompletedNCT01227356Phase 2
- Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid LeukemiaStatus unknownNCT01227135Phase 2
- Treatment Study for Children and Adolescents With Acute Promyelocitic LeukemiaStatus unknownNCT01226303Phase 3
- Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALLCompletedNCT01225874Not applicable
- An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)CompletedNCT01224093
- Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid LeukemiaTerminatedNCT01222143Phase 1/2
- Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)SuspendedNCT01222013Phase 2